This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Statistics and Research Methods  • Diagnosis  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

M. J. Friedrich

JAMA. 2008;300(22):2595-2597.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

With more than 5 million people in the United States diagnosed with Alzheimer disease (AD)—a number that is expected to triple in the next few decades—researchers are hotly pursuing effective therapies to treat the condition. One of the keys to doing so, say experts in the field, is finding a way to detect AD in its earliest stages, as well as gaining a better understanding of AD pathogenesis.

EARLIER DETECTION

Earlier detection of AD is crucial to diminishing its impact. By the time most people become symptomatic—even mildly so—and certainly by the time they have clinical AD, a lot of damage has already been done, said Ronald Petersen, MD, PhD, of the Mayo Clinic College of Medicine in Rochester, Minn.

In this image of a researcher viewing a specimen of brain tissue from the frontal cortex of a person who had Alzheimer disease, several brown amyloid plaques, a characteristic . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?